Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | ALOX5 | P09917 | 7/20 | 0.37 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.35 |
| ▸ | TTPA | P49638 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | NR1I2 | O75469 | 2/20 | 0.34 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.30 |
| ▸ | SRC | P12931 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4459202 | 0.80 | TSHR (0.45) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13592921 | 0.80 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL6906681 | 0.76 | ALOX5 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13431163 | 0.69 | ALOX5 (0.36) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL12713304 | 0.69 | CYP3A4 (0.42) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL4472285 | 0.68 | CYP3A4 (0.61) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL8543929 | 0.68 | PTGS1 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL8542784 | 0.67 | PSEN1 (0.30) | — | |
| SCHEMBL1567962 | 0.67 | ALOX5 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR | |
| SCHEMBL13309507 | 0.67 | ALOX5 (0.41) | PTGS1PTGS2CYP1A2CYP3A4TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 73 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3388426-B1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ BV (NL) | 2023-07-05 | — | — | EP | claimed |
| CN-116322661-A | Chromanol compounds for the treatment of heart failure | 萨尔法泰克有限公司 | 2023-06-23 | — | — | CN | claimed |
| CN-107660148-B | Compounds for preventing or treating organ damage | 萨尔法泰克有限公司 | 2021-03-09 | — | — | CN | claimed |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2019-01-08 | — | — | US | claimed |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2018-02-08 | — | — | US | claimed |
| US-9789086-B1 | N-(5-arylamido-2-methylphenyl)-5-methylisooxazole-4-carboxamide deravative, pharmaceutical acceptable salt thereof, method for preparation therof and FMS kinase inhibitor comprising the same as anactive ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-10-17 | — | — | US | claimed |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-09-28 | — | — | US | claimed |
| US-9540348-B2 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRYUNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2017-01-10 | — | — | US | claimed |
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | INDUSTRY-UNIVERSITY COOPERATION FOUNDATION HANYANG UNIVERSITY ERICA CAMPUS (KR) | 2016-07-14 | — | — | US | claimed |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | MPM ASSET MANAGEMENT INVESTORS 2002 BVIII LLC | 2003-04-03 | — | — | US | claimed |
| EP-1276730-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYx Therapeutics (US) | 2003-01-22 | — | — | EP | claimed |
| EP-0801063-B1 | Thiazolidinedione derivatives having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them | REDDYS LAB LTD DR (IN) | 2003-01-15 | — | — | EP | claimed |
| WO-2001081328-A2 | THIAZOLIDINEDIONE ANALOGUES AND THEIR USE FOR THE TREATMENT OF DIABETES | ARYX THERAPEUTICS (US) | 2001-11-01 | — | — | WO | claimed |
| WO-2023163596-A1 | CHROMANOL COMPOUNDS FOR TREATMENT OR PROPHYLAXIS OF AGEING-ASSOCIATED DISORDERS | SULFATEQ B.V. (NL) | 2023-08-31 | — | — | WO | disclosed |
| EP-3388426-B1 | COMPOUNDS FOR PROTECTION OF CELLS | SULFATEQ BV (NL) | 2023-07-05 | — | — | EP | disclosed |
| CN-116322661-A | Chromanol compounds for the treatment of heart failure | 萨尔法泰克有限公司 | 2023-06-23 | — | — | CN | disclosed |
| US-4939128-A | Antiischemic agents; circulatory disorders | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-07-03 | — | — | US | disclosed |
| CN-1037341-A | Xitix-2-phosphoric acid ester | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1989-11-22 | — | — | CN | disclosed |
| EP-0339486-A2 | Ester of ascorbic acid 2-phosphate | Takeda Chemical Industries, Ltd. (JP) | 1989-11-02 | — | — | EP | disclosed |
| US-4018799-A | INTERMEDIATES FOR TOCOPHEROL | HOFFMANN-LA ROCHE INC. (US) | 1977-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160200706-A1 | Imidazole-1-yl pyrimidine derivatives, or pharmacutically acceptable salt thereof, and pharmaceutic composition comprising the same as an active ingredient | BRAF, ARAF, NRAS | PTGS1 3337/4885PTGS2 3822/4885CYP1A2 2586/4885 |
| US-20170273947-A1 | N-(5-ARYLAMIDO-2-METHYLPHENYL)-5-METHYLISOOXAZOLE-4-CARBOXAMIDE DERAVATIVE, PHARMACEUTICAL ACCEPTABLE SALT THEREOF, METHOD FOR PREPARATION THEROF AND FMS KINASE INHIBITOR COMPRISING THE SAME AS ANACTIVE INGREDIENT | ABL1, FLT3, MERTK | PTGS1 3540/4885PTGS2 3518/4885CYP1A2 2372/4885 |
| US-20180037589-A1 | THIENODIAZEPINE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME AS ACTIVE INGREDIENT | RET, PDGFRB, FLT3 | PTGS1 1850/4885PTGS2 3080/4885CYP1A2 2972/4885 |
| US-10174047-B2 | Thienodiazepine derivatives or pharmaceutically acceptable salts thereof, and pharmaceutical composition including the same as an active ingredient | PDGFRB, RET, PDGFRA | PTGS1 1581/4885PTGS2 2913/4885CYP1A2 2485/4885 |
| US-20030064972-A1 | Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis | LIPA, LIPC, CETP | PTGS1 1370/4885PTGS2 814/4885CYP1A2 254/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.